Earnings summaries and quarterly performance for SUTRO BIOPHARMA.
Executive leadership at SUTRO BIOPHARMA.
Jane Chung
Detailed
Chief Executive Officer
CEO
Barbara Leyman
Detailed
Chief Business Development Officer
David Pauling
Detailed
General Counsel and Chief Administrative Officer
Greg Chow
Detailed
Chief Financial Officer
Hans-Peter Gerber
Detailed
Chief Scientific Officer
Venkatesh Srinivasan
Detailed
Chief Technical Operations Officer
Board of directors at SUTRO BIOPHARMA.
Research analysts who have asked questions during SUTRO BIOPHARMA earnings calls.
Edward Tenthoff
Piper Sandler Companies
2 questions for STRO
Also covers: ARVN, ARWR, CAPR +14 more
Jay Olson
Oppenheimer & Co. Inc.
2 questions for STRO
Also covers: ACAD, AMGN, BIIB +22 more
Reni Benjamin
Citizens JMP Securities
2 questions for STRO
Also covers: ALLO, BCAB, BGNE +7 more
Jiale Song
Jefferies Financial Group Inc.
1 question for STRO
Also covers: ACRS, CRVS, CTMX +12 more
Roger Song
Jefferies
1 question for STRO
Also covers: AADI, AKBA, ALT +13 more
Recent press releases and 8-K filings for STRO.
Sutro Provides Pipeline and Financial Update at Healthcare Conference
STRO
New Projects/Investments
Guidance Update
Product Launch
- Sutro announced that the first patient cohort has been dosed in the Phase 1 study for its tissue factor ADC, STRO-004, with top-line data anticipated by mid-2026.
- The company plans to file an Investigational New Drug (IND) application for its integrin beta-6 ADC (STRO-006) in 2026 and is developing a dual payload ADC (STRO-227) targeting PTK7, designed to overcome resistance to single payload ADCs.
- Sutro's cash runway has been extended into the middle of 2027, reflecting strategic efforts to reduce burn and externalize manufacturing.
- In collaboration with Astellas, Sutro is advancing an immunostimulatory ADC program, with the first program expected to enter the clinic in early 2026.
5 days ago
Sutro Biopharma Details XpressCF Platform and Clinical Pipeline Progress
STRO
New Projects/Investments
Guidance Update
- Sutro Biopharma's XpressCF platform enables the development of next-generation antibodies, including ADCs with 2-3 fold higher drug exposure and site-specific conjugation.
- The company has dosed the first cohort of patients in its Phase 1 study for STRO-004, a tissue factor ADC, and anticipates top-line data by the middle of next year (mid-2026). STRO-004 is designed for improved safety and efficacy, with a high non-severely toxic dose (HNSTD) of 50 mg/kg.
- Sutro plans to file an IND for its integrin beta-6 ADC (STRO-006) next year (2026) and is developing dual payload ADCs to overcome resistance to single payload ADCs.
- The company's partnership with Astellas is developing immunostimulatory ADCs, with Astellas' first program expected to enter the clinic early next year (2026).
- Sutro has extended its cash runway into the middle of 2027, not including potential milestones from partnerships.
5 days ago
Sutro Provides Update on XpressCF Platform, Clinical Pipeline, and Financial Runway
STRO
New Projects/Investments
Guidance Update
Product Launch
- Sutro's XpressCF platform enables next-generation ADCs with enhanced drug exposure, site-specific conjugation, and dual payloads, aiming to overcome resistance to single payload ADCs.
- The company has dosed the first cohort of patients in the Phase 1 study for its tissue factor ADC, STRO-004, with IND clearance in late October and top-line data anticipated by mid-2025.
- Sutro plans to file an IND for an integrin beta-6 ADC next year and is developing a dual payload ADC (STRO-227) targeting PTK7, designed for improved efficacy and safety.
- Sutro has extended its cash runway into mid-2027 by reducing burn and externalizing manufacturing, following a strategic pivot in March.
5 days ago
Sutro Biopharma Outlines Strategic Reset and Pipeline Advancements at 2025 R&D Day
STRO
New Projects/Investments
Management Change
Guidance Update
Nov 12, 2025, 3:00 PM
Sutro Biopharma Details Strategic Reset and Advances Differentiated ADC Pipeline at 2025 R&D Day
STRO
New Projects/Investments
Guidance Update
- Sutro Biopharma has undergone a strategic reset, focusing on a differentiated Antibody-Drug Conjugate (ADC) pipeline and has extended its cash runway to the middle of 2027.
- The lead program, STRO-004, a tissue factor ADC, is now active and enrolling in the clinic, with initial top-line data anticipated in mid-2026. Preclinical data showed a high non-severe toxic dose (HNSTD) of 50 mg/kg and anti-tumor activity at doses as low as 1 mg/kg.
- The company is advancing STRO-006, an integrin beta-6 ADC, with an Investigational New Drug (IND) filing targeted for 2026.
- Sutro is also progressing dual payload ADCs, including its first wholly-owned program targeting PTK7, aiming for clinic entry as early as 2026-2027, and an Astellas-partnered iADC program expected to enter the clinic in early 2026.
- Sutro's ADC technology is designed to optimize every component (antibody, linker, payload) to achieve improved safety and efficacy, allowing for higher drug exposure and potentially overcoming resistance.
Nov 12, 2025, 3:00 PM
Sutro Details Strategic Reset and Clinical Pipeline Progress at R&D Day
STRO
New Projects/Investments
- Sutro has completed a strategic reset with a new leadership team, reducing its workforce from approximately 350 FTEs to 130, and extending its cash runway to mid-2027.
- The company's lead program, STRO-004, a tissue factor ADC, is now active and enrolling in the clinic, with initial top-line data expected in mid-2026.
- Sutro's pipeline includes STRO-006 (integrin beta-6 ADC) with an IND planned for 2026, and its first wholly-owned dual payload PTK7 ADC aiming for clinic entry in 2026-2027.
- An Astellas-partnered immunostimulatory ADC (iADC) program is also expected to enter the clinic in early 2026.
- Sutro emphasizes its differentiated ADC technology, which allows for optimization of all components (antibody, linker, payload) to achieve higher drug exposure and a wider therapeutic window, particularly for dual payload ADCs designed to overcome resistance and improve efficacy.
Nov 12, 2025, 3:00 PM
Sutro Biopharma Reports Q3 2025 Financial Results and STRO-004 IND Clearance
STRO
Earnings
Guidance Update
New Projects/Investments
- Sutro Biopharma reported cash, cash equivalents and marketable securities of $167.6 million as of September 30, 2025, with an expected cash runway into at least mid-2027 due to operational efficiencies and anticipated near-term milestone payments.
- The company received U.S. FDA clearance of its Investigational New Drug (IND) application for STRO-004, its Tissue Factor ADC, and expects to dose the first patient before year-end 2025.
- For the third quarter ended September 30, 2025, revenue was $9.7 million, an increase from $8.5 million in the prior year period, while total operating expenses decreased to $58.2 million from $76.4 million in Q3 2024.
Nov 6, 2025, 9:45 PM
Sutro Biopharma Reports Q3 2025 Results and STRO-004 IND Clearance
STRO
Earnings
New Projects/Investments
Guidance Update
- Sutro Biopharma reported $167.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, with a cash runway projected into at least mid-2027.
- The company received U.S. FDA clearance for its Investigational New Drug (IND) application for STRO-004, a Tissue Factor ADC, and anticipates dosing the first patient before year-end.
- For the third quarter of 2025, revenue was $9.7 million, primarily from the Astellas collaboration, and total R&D and G&A expenses were $48.6 million.
- Sutro will host a virtual R&D Day on November 12, 2025, to provide updates on its next-generation ADC programs.
Nov 6, 2025, 9:30 PM
Sutro Biopharma Announces Operational Restructuring
STRO
Layoffs
Guidance Update
New Projects/Investments
- Sutro Biopharma, Inc. announced an operational restructuring to prioritize its three ADC programs and research and development collaborations.
- This restructuring is expected to extend the company's cash runway into at least mid-2027.
- The plan includes a workforce reduction of approximately one-third of employees.
- Total estimated costs for the restructuring are between $4.1 million and $4.3 million, with the majority expected to be paid in Q4 2025.
- The company anticipates initial clinical data from its STRO-004 program in 2026.
Sep 29, 2025, 9:15 PM
Sutro Biopharma Announces Organizational Restructuring
STRO
Layoffs
Guidance Update
- Sutro Biopharma announced an organizational restructuring to prioritize its three antibody drug conjugate (ADC) programs and research and development collaborations.
- This restructuring, along with expected near-term milestone payments, is anticipated to extend the company's cash runway into at least mid-2027.
- The restructuring will result in a planned workforce reduction of approximately one-third of employees.
- The company expects to announce initial clinical data from STRO-004 in 2026 and initiate clinical studies for at least one additional ADC program.
Sep 29, 2025, 9:05 PM
Quarterly earnings call transcripts for SUTRO BIOPHARMA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more